Genervon Continues to Focus on Nerve Cell Development Factor as ALS Treatment
Genervon Biopharmaceuticals says its efforts to develop treatments for ALS and other neurodegenerative diseases continue to focus on a factor…
Articles by Patricia Inácio, PhD
Arimoclomol Has Potential to Slow ALS Patients’ Functional Decline, Phase 2/3 Trial Shows
A Phase 2/3 clinical trial showed that arimoclomol has the potential to slow ALS patients’ functional decline, according its maker, …
Interleukin-4 Reduces Symptoms in Early, But Not Late, Stages of ALS, Mouse Study Shows
Interleukin 4 reduces the severity of clinical symptoms during the early phase of amyotrophic lateral sclerosis (ALS), but has no…
Arizona State University to Grow Human Neurons in Search of New Therapies for Neurodegenerative Diseases
Arizona State University will soon launch a new biomanufacturing platform to grow human neurons in vitro to develop and test…
Easing the Nerve Cell Traffic Jam May Be a Way to Treat ALS, Research Suggests
A traffic jam inside nerve cells is a feature of most forms of amyotrophic lateral sclerosis and frontotemporal dementia, a…
American CryoStem’s Atcell Not Approved for ALS, Other Neurodegenerative Diseases, FDA Warns
The U.S. Food and Drug Administration (FDA) has issued a warning to the American CryoStem Corporation of Monmouth Junction,…
Canadian Clinical Trial Recruiting ALS Patients to Test Antipsychotic Therapy Orap
Researchers at the University of Calgary in Canada are enrolling amyotrophic lateral sclerosis (ALS) patients for a Phase…
NurOwn, Now in Phase 3 Trial, Shows Potential in ALS Patients with Rapid Progression, BrainStorm’s CMO Says in Interview
BrainStorm Cell Therapeutics released new data on potential biomarkers from its Phase 2 trial investigating NurOwn, the company’s cell therapy…
ALS Patients’ Lung-function Decline Scores Can Predict Breathing Failure, Study Reports
The rate of ALS patients’ lung-function decline can predict their risk of breathing failure, their need for assisted ventilation, and…
FDA-Approved Schizophrenia Medicine Orap Appears to Benefit ALS Patients, Canadian Study Reports
The schizophrenia therapy Orap (pimozide) may be able to prevent the progression of ALS, Canadian researchers report. The team confirmed…